Bristol Myers Squibb (CELG-RI) Work In Process (2010 - 2013)
Bristol Myers Squibb (CELG-RI) reported Work In Process of $884.0 million for Q1 2013, up 22.61% year-over-year from $721.0 million in Q1 2012, and up 8.6% quarter-over-quarter from $814.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Work In Process (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 4 years of Work In Process data on file, last reported at $884.0 million in Q1 2013.
- Work In Process for Q1 2013 came in at $884.0 million, up 22.61% year-over-year; the trailing twelve-month figure through Mar 2013 was $884.0 million (up 22.61% YoY), and the FY2012 annual result was $814.0 million, up 26.01% from the prior year.
- Work In Process advanced to $884.0 million in Q1 2013 per CELG-RI's latest filing, from $814.0 million in the prior quarter.
- Over five years, Work In Process peaked at $884.0 million in Q1 2013 and troughed at $608.0 million in Q4 2010.
- A 4-year average of $739.3 million and a median of $715.0 million in 2011 frame the typical range for Work In Process.
- On a YoY basis, Work In Process climbed as much as 26.01% in 2012 and fell as far as 4.49% in 2012.
- A 4-year view of Work In Process shows it stood at $608.0 million in 2010, then gained by 6.25% to $646.0 million in 2011, then climbed by 26.01% to $814.0 million in 2012, then advanced by 8.6% to $884.0 million in 2013.
- Business Quant data shows CELG-RI's Work In Process at $884.0 million in Q1 2013, $814.0 million in Q4 2012, and $868.0 million in Q3 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 884.00 Mn |
| Dec 31, 2012 | 814.00 Mn |
| Sep 30, 2012 | 868.00 Mn |
| Jun 30, 2012 | 755.00 Mn |
| Mar 31, 2012 | 721.00 Mn |
| Dec 31, 2011 | 646.00 Mn |
| Sep 30, 2011 | 709.00 Mn |
| Jun 30, 2011 | 698.00 Mn |
| Mar 31, 2011 | 690.00 Mn |
| Dec 31, 2010 | 608.00 Mn |